share_log

恒瑞医药(600276.SH):SHR-2173注射液获得药物临床试验批准通知书

Hengrui Pharmaceutical (600276.SH): SHR-2173 injection obtained drug clinical trial approval notice

Gelonghui Finance ·  May 14 05:21

Gelonghui May 14 丨 Hengrui Pharmaceutical (600276.SH) announced that its subsidiary Guangdong Hengrui Pharmaceutical Co., Ltd. has received approval from the State Drug Administration to issue a “Pharmaceutical Clinical Trial Approval Notice” for SHR-2173 injections and will conduct clinical trials in the near future. SHR-2173 injection is a therapeutic biological product independently developed by the company. It can exert anti-inflammatory and immune-suppressing biological effects by targeting abnormally activated immune cells. It is expected to reduce autoantibody levels, improve the disease activity status of patients with IgA nephropathy, and bring new treatment options to patients. Currently, there are no drugs similar to SHR-2173 on the market or in clinical development at home or abroad.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment